Craig Sorce
Optometrist · Saint Louis, MONPI 1861520819
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,134 of the $7,979 with a category attached, or 76.9%. 26 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 27.3% of the total. Reporting peaked in 2019 at $2,917 and has fallen 61.2% since, to $1,131 in 2025. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Alcon$873
- Bausch & Lomb Americas Inc.$456
- Oyster Point Pharma, Inc.$321
- Aerie Pharmaceuticals, Inc.$263
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,84523%
- Food & beverage$6,13477%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $2,176 |
| AbbVie(2 entities) | 100 | $1,783 |
| Alcon | 47 | $873 |
| Bausch & Lomb Americas Inc. | 29 | $456 |
| Oyster Point Pharma, Inc. | 12 | $321 |
| Aerie Pharmaceuticals, Inc. | 16 | $263 |
| Astellas Pharma US Inc | 4 | $224 |
| Kala Pharmaceuticals, Inc. | 11 | $215 |
| Mallinckrodt Hospital Products Inc. | 7 | $208 |
| Thea Pharma Inc. | 10 | $197 |
| Sun Pharmaceutical Industries Inc. | 10 | $189 |
| Tarsus Pharmaceuticals, Inc. | 6 | $185 |
| Novartis | 12 | $185 |
| Johnson & Johnson Vision Care, Inc. | 3 | $125 |
| Eyevance Pharmaceuticals LLC | 6 | $95 |
| Biotissue Holdings Inc. | 11 | $87 |
| Harrow Eye, LLC | 4 | $87 |
| LKC Technologies, Inc. | 1 | $72 |
| Ocular Therapeutix, Inc. | 3 | $60 |
| Coopervision Inc. | 1 | $59 |
| Sight Sciences, Inc. | 2 | $29 |
| Genentech USA, Inc. | 1 | $23 |
| Glaukos Corporation | 1 | $22 |
| Amgen | 1 | $19 |
| Rxsight Inc | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,979 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 149 | $76,432 |
| XdemvyLotilaner | 17 | $31,454 |
| RocklatanNetarsudil Mesylat/Latanoprost | 55 | $29,801 |
| VyzultaLatanoprostene Bunod | 48 | $21,197 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $14,738 |
| RestasisCyclosporine | 15 | $14,408 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 97 | $14,272 |
| Travoprost | 51 | $9,747 |
| XiidraLifitegrast | 14 | $9,572 |
| RhopressaNetarsudil Mesylate | 19 | $7,918 |
| Alphagan PBrimonidine Tartrate | 24 | $6,012 |
| Latanoprost | 454 | $3,954 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $3,149 |
| Brimonidine Tartrate | 60 | $2,579 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $2,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,783 | $111,590224 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $263 | $37,71974 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $185 | $31,45417 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $456 | $30,77062 claims |
| AlconSimbrinza | $873 | $3,14911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Saint Louis
- John McGrealSaint Louis$126K
- Ariel CerenzieSaint Louis$76K
- Paul LuongSaint Louis$44K
- Robert EnsleySaint Louis$38K
- Andrew RoyerSaint Louis$23K
- Robert BrusattiSaint Louis$20K
- Edward BennettSaint Louis$13K
- Julie DekinderSaint Louis$8K
- Erin SullivanSaint Louis$6K
- Kathryn NoonanSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.